{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:03:29Z","timestamp":1790435009481,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL131696"],"award-info":[{"award-number":["R01HL131696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vaccine.2021.08.077","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T07:39:22Z","timestamp":1630309162000},"page":"5780-5786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9978-253X","authenticated-orcid":false,"given":"Alexandra","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-250X","authenticated-orcid":false,"given":"Maureen","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5712-4739","authenticated-orcid":false,"given":"Bryce","family":"Chackerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.08.077_b0005","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.08.077_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IPRP.S133088","article-title":"Cardiovascular disease as a leading cause of death: how are pharmacists getting involved?","volume":"8","author":"Mc Namara","year":"2019","journal-title":"Integrated Pharm Res Practice"},{"key":"10.1016\/j.vaccine.2021.08.077_b0015","first-page":"1","article-title":"Deaths: final data for 2008","volume":"59","author":"Mini\u00f1o","year":"2011","journal-title":"Natl Vital Stat Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.077_b0020","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.amjcard.2010.05.030","article-title":"30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999\u20132006","volume":"106","author":"Cohen","year":"2010","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.077_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.077_b0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and Inflammation in Atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.077_b0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11883-008-0060-9","article-title":"Triglycerides and risk for coronary artery disease","volume":"10","author":"McBride","year":"2008","journal-title":"Curr Atheroscl Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.077_b0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/dc16-1958","article-title":"Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study","volume":"40","author":"Lee","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.077_b0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12325-016-0462-y","article-title":"A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids","volume":"34","author":"Karalis","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2021.08.077_b0050","doi-asserted-by":"crossref","unstructured":"Effects of extended-release niacin with laropiprant in high-risk patients. New Engl J Med 2014;371:203\u201312.","DOI":"10.1056\/NEJMoa1300955"},{"key":"10.1016\/j.vaccine.2021.08.077_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/VHRM.S158641","article-title":"Nonadherence to statins: individualized intervention strategies outside the pill box","volume":"14","author":"Lansberg","year":"2018","journal-title":"Vascular Health Risk Manage"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.077_b0060","article-title":"New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases","volume":"17","author":"Su","year":"2018","journal-title":"Lipids Health Dis"},{"issue":"37","key":"10.1016\/j.vaccine.2021.08.077_b0065","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.vaccine.2021.08.077_b0070","doi-asserted-by":"crossref","first-page":"11766","DOI":"10.1073\/pnas.0705041104","article-title":"Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice","volume":"104","author":"Desai","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2021.08.077_b0075","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1210\/en.2005-0476","article-title":"Transgenic angiopoietin-Like (Angptl)4 overexpression and targeted disruption of Angptl4 and Angptl3: regulation of triglyceride metabolism","volume":"146","author":"K\u00f6Ster","year":"2005","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.077_b0080","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2021.08.077_b0085","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3Mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2021.08.077_b0090","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.077_b0100","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0105","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.077_b0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.077_b0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.08.077_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pharmtox-061008-103129","article-title":"Immunodrugs: therapeutic VLP-based vaccines for chronic diseases","volume":"49","author":"Jennings","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.coviro.2013.05.004","article-title":"Virus-induced humoral immunity: on how B cell responses are initiated","volume":"3","author":"Zabel","year":"2013","journal-title":"Curr Opin Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.08.077_b0130","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.4049\/jimmunol.180.9.5816","article-title":"Virus-Like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model","volume":"180","author":"Chackerian","year":"2008","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2021.08.077_b0135","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J","article-title":"Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation","volume":"32","author":"Jegerlehner","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.08.077_b0140","doi-asserted-by":"crossref","DOI":"10.1515\/BC.2008.064","article-title":"The coming of age of virus-like particle vaccines","volume":"389","author":"Jennings","year":"2008","journal-title":"Biol Chem"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI11849","article-title":"Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies","volume":"108","author":"Chackerian","year":"2001","journal-title":"J Clin Investig"},{"issue":"43","key":"10.1016\/j.vaccine.2021.08.077_b0150","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2021.08.077_b0155","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1016\/j.vaccine.2010.04.049","article-title":"Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7","volume":"28","author":"Caldeira","year":"2010","journal-title":"Vaccine"},{"issue":"37-39","key":"10.1016\/j.vaccine.2021.08.077_b0160","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2006.05.059","article-title":"Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-\u03b2 without concomitant T cell responses","volume":"24","author":"Chackerian","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.077_b0165","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","article-title":"Atypical angiopoietin-like protein that regulates ANGPTL3","author":"Quagliarini","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.077_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-25237-7","article-title":"Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease","volume":"8","author":"Biterova","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.08.077_b0175","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1074\/jbc.M807899200","article-title":"Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)","volume":"284","author":"Lee","year":"2009","journal-title":"J Biol Chem"},{"issue":"43","key":"10.1016\/j.vaccine.2021.08.077_b0180","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","article-title":"Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3)","volume":"278","author":"Ono","year":"2003","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.vaccine.2021.08.077_b0185","doi-asserted-by":"crossref","first-page":"15747","DOI":"10.1074\/jbc.M110.217638","article-title":"Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity","volume":"286","author":"Lei","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2021.08.077_b0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","article-title":"Postprandial hypertriglyceridemia as a coronary risk factor","volume":"431","author":"Bor\u00e9n","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.vaccine.2021.08.077_b0195","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1194\/jlr.M500005-JLR200","article-title":"Differential regulation and properties of angiopoietin-like proteins 3 and 4","volume":"46","author":"Ge","year":"2005","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.077_b0200","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vaccine.2021.08.077_b0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.24.1.87","article-title":"Plasma lipoprotein lipase after subcutaneous heparin","volume":"24","author":"Connor","year":"1961","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2021.08.077_b0210","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease","volume":"374","author":"Myocardial Infarction","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2021.08.077_b0215","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1194\/jlr.P039875","article-title":"Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis","volume":"54","author":"Minicocci","year":"2013","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.077_b0220","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.08.077_b0230","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.077_b0235","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.077_b0240","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCRESAHA.120.317128","article-title":"LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase","volume":"127","author":"Wu","year":"2020","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.077_b0245","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1073\/pnas.0409564102","article-title":"Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart","volume":"102","author":"Yu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.08.077_b0250","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180557","article-title":"A review of the multifunctionality of angiopoietin-like 4 in eye disease","volume":"38","author":"Yang","year":"2018","journal-title":"Biosci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0255","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/eji.200737989","article-title":"Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis","volume":"38","author":"Spohn","year":"2008","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.077_b0260","doi-asserted-by":"crossref","first-page":"e1408749","DOI":"10.1080\/2162402X.2017.1408749","article-title":"Virus-like particle display of HER2 induces potent anti-cancer responses","volume":"7","author":"Palladini","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.vaccine.2021.08.077_b0265","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.077_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0118-4","article-title":"Q\u00df Virus-like particle-based vaccine induces robust immunity and protects against tauopathy","volume":"4","author":"Maphis","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.077_b0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","article-title":"A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity","volume":"25","author":"Amb\u00fchl","year":"2007","journal-title":"J Hypertens"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.077_b0280","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.077_b0285","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2006.01.040","article-title":"Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults","volume":"117","author":"Kundig","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.077_b0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.08.077_b0295","article-title":"Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes","volume":"12","author":"Myers","year":"2019","journal-title":"Circulation: Cardiovasc Quality Outcomes"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:01:17Z","timestamp":1759402877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21011257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":59,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0264410X21011257"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.077","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.08.434130","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}